Table I.
Detailed information of the datasets in GEO and TCGA patients.
| GEO ID | GSE14520 | GSE3500 | GSE76427 | GSE84402 | TCGA |
|---|---|---|---|---|---|
| Total no. of patients | 22 | 82 | Not mentioned | 14 | 371 |
| Total no. of samples | 132 | 193 | 167 | 14 | 373 |
| No. of non-tumor samples | 66 (paired non-tumor samples) | 74 (non-tumor samples) | 52 (adjacent non-tumor tissues) | 14 (>5 cm laterally from the edge of the cancerous) region | 42 (healthy tissues) |
| No. of primary HCC samples | 66 (tumor samples) | 102 (tumor samples from HBV+ patients) | 115 (primary tumor tissues) | 14 (percentage of tumor cells >70%) | 84 (tumor samples) |
| Tumor types | Hepatocellular carcinoma | Hepatocellular carcinoma | Hepatocellular carcinoma | Hepatocellular carcinoma | Hepatocellular carcinoma |
| Grading of tumors (TNM stage) | No subdivision | No subdivision | No subdivision | No subdivision | Stage II |
| Pathological grade | No subdivision | No subdivision | No subdivision | No subdivision | No subdivision |
| Comment | N.A. | N.A. | Percentage of HCC patients with HBV infection and cirrhosis were 46% and 54%. | N.A. | Using CRN (Cancer RNA-Seq Nexus tool) for analysis. |
GEO, Gene Expression Omnibus; TCGA, The Cancer Genome Atlas; HCC, hepatocellular carcinoma; TNM, tumor node metastasis; HBV, hepatitis B virus.